Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below 50-Day Moving Average – Here’s Why

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$17.72 and traded as low as C$16.00. Cipher Pharmaceuticals shares last traded at C$16.31, with a volume of 17,402 shares.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$17.00 target price on Cipher Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of C$17.00.

Cipher Pharmaceuticals Stock Performance

The company has a 50-day moving average of C$17.72 and a 200 day moving average of C$16.05. The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of C$414.13 million, a PE ratio of 13.71 and a beta of 1.10.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its earnings results on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%.The business had revenue of C$17.39 million during the quarter. Equities research analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.